Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20671574 | 1.00 | SIGMAR1 (0.34) | SIGMAR1CYP1A2MEN1ALDH1A1LMNA | |
| SCHEMBL28157000 | 0.82 | CYP1A2 (0.39) | CYP1A2MEN1ALDH1A1LMNAALOX12 | |
| SCHEMBL2996130 | 0.78 | CYP1A2 (0.36) | CYP1A2MEN1ALDH1A1LMNAALOX12 | |
| SCHEMBL628519 | 0.76 | SMN1; SMN2 (0.40) | SIGMAR1CYP1A2MEN1ALDH1A1LMNA | |
| SCHEMBL2985857 | 0.72 | CYP1A2 (0.41) | SIGMAR1CYP1A2 | |
| SCHEMBL3001150 | 0.71 | CYP1A2 (0.45) | SIGMAR1CYP1A2 | |
| SCHEMBL23894764 | 0.69 | MEN1 (0.33) | SIGMAR1MEN1ALDH1A1LMNAALOX12 | |
| SCHEMBL21372361 | 0.68 | — | — | |
| SCHEMBL27422699 | 0.68 | CHRM1 (0.37) | MEN1ALDH1A1LMNAALOX12KMT2A | |
| SCHEMBL14553280 | 0.67 | CYP1A2 (0.39) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018064092-A1 | METHOD FOR TREATING CANCER USING A COMBINATION OF DNA-DAMAGING AGENTS AND DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-04-05 | — | — | WO | disclosed |